A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma
Clinical trial NCT06337617 · COMPLETED
Trial details
- NCT number
- NCT06337617
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-05-10
- Primary completion
- 2023-06-29
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.